Option chain shows key data for Fortress Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Fortress Biotech.

Fortress Biotech (NASDAQ:FBIOP) Stock, Option Chain

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACRS

ADMA

FBIOP

GNPX

MRNA

ONTX

ONVO

PDSB

REXN

TTNP

XERS

ZSAN

13 Healthcare Stocks Moving In Wednesday&#39;s Pre-Market Session

12 Biotechnology Stocks Moving In Wednesday&#39;s Pre-Market Session

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc

Earnings

Press Releases

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

News

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Financing

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Fortress Biotech to Participate in October 2024 Investor Conferences

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

General

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

ATXI

CKPT

DERM

FBIO

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Fortress Biotech

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Comments

Fortress Biotech

Fortress Biotech (FBIOP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell